Investment Rating - The report assigns an "Accumulate" rating for the beauty and personal care sector, indicating a positive outlook for the industry [6]. Core Insights - The beauty and personal care sector has experienced a significant pullback since August, with leading high-growth companies' valuations returning to 20-30x, and PEG ratios mostly below 1x, suggesting the sector is expected to bottom out [3][6]. - Lin Qingxuan is set to go public, focusing on the oil-based skincare segment, with a projected doubling of performance in the first half of 2025 [3][6]. Summary by Sections Market Performance - The beauty and personal care sector saw a decline of over 15% since August, with leading companies experiencing a valuation correction to 20-30x. The sector's maximum drawdown reached 17%, with top companies seeing declines of over 30% [6][8]. - The Shenyuan Beauty Care Index recorded a maximum increase of 19% in 2025, with key growth stocks like Ruoyuchen, Shangmei, and Maogeping achieving maximum gains of 239%, 198%, and 121% respectively [6][8]. Company Highlights - Lin Qingxuan, which is set to launch its IPO, plans to issue 13.97 million shares at an offering price of 77.77 HKD per share, corresponding to a market capitalization of 10.9 billion HKD. The company has secured cornerstone investors including Fidelity and others, with total subscriptions reaching 62 million USD [6][8]. - Lin Qingxuan's revenue for the first half of 2025 is projected at 1.05 billion CNY, reflecting a year-on-year increase of 98%, with a net profit of 182 million CNY, up 110%. The company's main product, a camellia oil essence, generated 480 million CNY in revenue, marking a 176% increase [6][8]. Investment Recommendations - The report suggests a bottom-up selection of stocks with product and channel innovations, highlighting strong growth potential in the beauty and personal care sector. Recommended stocks include: 1. High-growth brands: Ruoyuchen, Shangmei, Maogeping 2. Stable fundamentals with potential for improvement: Dengkang Oral, Shanghai Jahwa, Shuiyang, Jinbo Biological, Beitaini, Marubi, Qingsong 3. Stocks expected to bottom out: Pola, Juzibio, Lafang, Runben, Meilitiantian Medical Health, Furida, Huaxi Biological [6][7].

证券之星消息，12月19日医疗美容板块较上一交易日上涨2.13%，爱美客领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 145.80 | 2.81% | 4.06万 | | 5.8716 | | 920982 | 锦波生物 | 251.98 | 1.60% | 1.33万 | | 3.31亿 | | 000615 | *ST美谷 | 4.11 | 1.48% | 7.03万 | | 2875.42万 | | 688363 | 华熙生物 | 44.18 | 1.28% | 3.23万 | | 1.43亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入（元） 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | ...

Group 1 - The medical beauty sector experienced a decline of 0.27% compared to the previous trading day, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - The net inflow of main funds into the medical beauty sector was 253,500 yuan, while retail investors saw a net outflow of 701,410 yuan [2] Group 2 - The sector saw a net inflow of 676,060 yuan from speculative funds [2] - Detailed fund flow data for individual stocks in the medical beauty sector is available in the accompanying table [2]

Core Viewpoint - The collagen market is undergoing significant changes with the approval of new products from Chongshan Bio and Aibai Rui, expanding the competitive landscape in the animal-derived collagen sector. The focus is shifting towards differentiation in terms of cost-effectiveness, brand recognition, product safety, and efficacy as the market becomes increasingly crowded [1][2]. Group 1: New Product Approvals - Chongshan Bio's new product is the world's first collagen implant with a concentration of 45mg/ml, aiming to establish a strong product image through high concentration [2]. - Aibai Rui's new product targets specific needs by improving cheek smoothness, attempting to create a niche in the market despite similarities to existing products [4]. Group 2: Market Dynamics - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading the market due to their early entry and established brand recognition [6]. - New entrants are focusing on differentiation strategies, such as high-quality ingredients and innovative product forms, to compete effectively [6]. Group 3: Growth of Recombinant Collagen - The recombinant collagen market is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, surpassing the 27.7% CAGR of animal-derived collagen [8]. - The market size for recombinant collagen products in 2023 is estimated at 28.63 billion yuan, slightly below the 29.79 billion yuan for animal-derived collagen, indicating a shift in consumer preference towards recombinant options [8]. Group 4: Competitive Landscape and Future Outlook - The approval of new recombinant collagen products is intensifying competition, with companies like Jinjian Bio and others entering the market, challenging the previous dominance of Jinbo Bio [9]. - The future of the collagen market will likely see increased competition, with a focus on cost-effectiveness, brand strength, and product efficacy becoming critical for success [12].

Group 1 - The article provides an overview of the latest net asset values of various funds, highlighting the top-performing and bottom-performing funds as of December 16, 2025 [2][3] - The top 10 funds with the highest net value growth include Dongcai Economic Growth C, Dongcai Economic Growth A, and Green Innovation Growth A, among others, with growth rates ranging from 1.31% to 1.90% [2] - The bottom 10 funds with the lowest net value growth include Yongying Manufacturing Upgrade C and A, with declines of -6.25%, and other funds experiencing declines between -4.72% and -5.35% [3] Group 2 - The market analysis indicates a downward trend in the Shanghai Composite Index, with a trading volume of 1.74 trillion, and a significant number of stocks declining compared to those that rose [5] - Leading sectors include public transportation and hotel catering, which saw increases of over 2%, while mineral products and shipbuilding sectors experienced declines exceeding 3% [5] - The fund with the fastest net value growth is identified as Dongcai Economic Growth C, reflecting a strong performance in the current market conditions [5] Group 3 - The top holdings of the funds show a concentration in specific stocks, with the top 10 holdings accounting for 23.46% of the total portfolio in one fund, indicating a focused investment strategy [6] - Conversely, another fund's top 10 holdings represent 65.84% of its total portfolio, with significant declines in stocks like Hezhu Intelligent and Yongding Shares, suggesting a riskier investment profile [6] - The performance of these funds is influenced by their sector focus, with one fund leaning towards the electric power industry and another towards the North Exchange concept, impacting their relative market performance [6]

从资金流向上来看，当日医疗美容板块主力资金净流入6532.5万元，游资资金净流出1191.11万元，散户 资金净流出5341.39万元。医疗美容板块个股资金流向见下表： 证券之星消息，12月16日医疗美容板块较上一交易日上涨0.98%，爱美客领涨。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.56 | 2.02% | 4.62万 | 6.53 Z | | 688363 | 华熙生物 | 43.29 | -0.07% | 3.98万 | 1.74亿 | | 920982 | 锦波生物 | 262.15 | -0.32% | 1.66万 | 4.44 Z | | 000615 | *ST美谷 | 4.09 | -1.45% | 5.75万 | 2369.06万 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

Investment Rating - The report indicates a positive outlook for the cosmetics raw materials industry, highlighting the stable growth of the downstream cosmetics sector and the leading positions of companies like Weiqi Technology and Jiakai Biological [1]. Core Insights - The cosmetics raw materials industry in China is projected to grow from CNY 1,147.80 billion in 2019 to CNY 1,603.90 billion by 2024, with a compound annual growth rate (CAGR) of 6.9% [2][12]. - The peptide active ingredients market is expected to grow from CNY 11.2 billion in 2019 to CNY 21.7 billion by 2024, achieving a CAGR of 14.1% [2][16]. - The plant extract raw materials market is anticipated to increase from CNY 204.5 billion in 2019 to CNY 270.2 billion by 2024, with a CAGR of 6.5% [2][20]. - Weiqi Technology holds a 6.6% market share in the peptide raw materials sector, ranking first in China [2][25]. - Jiakai Biological has established a leading position in the plant extract efficacy raw materials field, with significant revenue growth [2][33]. Summary by Sections 1. Growth of the Cosmetics Raw Materials Industry - The cosmetics raw materials market in China is expected to reach CNY 1,604 billion by 2024, driven by the stable growth of the cosmetics industry [2][5]. - The global cosmetics market is projected to reach USD 550.3 billion in 2024, with China being the largest market [5][8]. 2. Performance of Weiqi Technology and Jiakai Biological - Weiqi Technology's revenue for the first half of 2025 is CNY 132 million, a year-on-year increase of 34.6%, with a net profit of CNY 40.2 million, up 68.76% [2][30]. - Jiakai Biological's revenue for the first three quarters of 2025 is CNY 195 million, reflecting a year-on-year growth of 7.91%, with a net profit of CNY 47.3 million, up 16.91% [2][37]. 3. Market Trends and Valuation - The median price-to-earnings (P/E) ratio for the North Exchange consumer service sector increased to 50.1X, indicating a slight upward trend [2][50]. - The total market capitalization of consumer service companies on the North Exchange rose from CNY 1,096.29 billion to CNY 1,152.85 billion [2][43]. 4. Competitive Landscape - The cosmetics raw materials industry is characterized by a low concentration, with many small-scale companies primarily serving domestic mid-to-low-end markets [2][12]. - The demand for active ingredients, particularly peptides, is growing rapidly, driven by consumer preferences for effective skincare products [2][15].

Group 1 - The medical beauty sector experienced a decline of 2.27% on December 15, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3867.92, down 0.55%, while the Shenzhen Component Index closed at 13112.09, down 1.1% [1] - A detailed table of individual stock performance in the medical beauty sector is provided [1] Group 2 - In terms of capital flow, the medical beauty sector saw a net outflow of 48.24 million yuan from main funds, while retail investors contributed a net inflow of 53.44 million yuan [2] - The net outflow from speculative funds was 5.20 million yuan [2] - A detailed table of capital flow for individual stocks in the medical beauty sector is included [2]

Group 1 - A-shares experienced a collective decline in major indices, with the Shanghai Composite Index dropping nearly 1% at one point, but the losses narrowed towards the end of the trading session [2] - Notable stocks such as Pudong Development Bank, Agricultural Bank of China, Industrial and Commercial Bank of China, Bank of China, China Petroleum, China Petrochemical, Kweichow Moutai, and China Life Insurance saw a sudden collective surge during the auction period [2] Group 2 - The North Securities 50 Index surged significantly in the afternoon, rising over 6% at one point and closing up 3.84% [3] - Individual stocks like Tianli Composite hit a 30% limit up, while Fujida and Xingtum Measurement Control rose over 13%, and Tianma New Materials increased by over 9% [4] - The North Securities Index sample stocks and reserve list will undergo regular adjustments, effective December 15, including companies like Five New Tunnel Equipment, Better Ray, Airo Technology, Shuguang Digital Innovation, Anda Technology, and Jinbo Biological [4] Group 3 - The ultra-high voltage concept stocks showed strong performance, with Tongguang Cable hitting a 20% limit up, while Zhongchao Holdings and Hualing Cable also reached their limit up, and Caneng Electric rose nearly 8% [5] - Institutions believe that 2026, as the start of the "14th Five-Year Plan," will present dual opportunities for the power equipment industry due to domestic demand expectations and external demand recovery [5] - CITIC Securities projects that investment in the power grid will maintain stable growth during the "14th Five-Year Plan," with an estimated total investment of approximately 3.8 trillion yuan from 2026 to 2030, corresponding to an average annual investment of about 750 billion yuan [5]

2025 年 12 月 14 日 北交所研究团队 北交所打新配置策略：精选高质新股机会，布局低估值高分红资产 ——北交所策略专题报告 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 2025 年北交所新股收益率较好，审核加快关注北交所具备大市值低估值企业 从 2025 年新股情况看北交所表现较好，北交所、上交所、深交所上市企业首日 涨跌幅均值分别为 354.69%、222.90%、206.84%，网上发行中签率均值为 0.0371%、0.0488%、0.0211%，首次发行市盈率均值 12.70X、40.22X、19.77X， 首次发行市净率均值 1.57X、2.39X、2.04X。从北交所发审会节奏上来看，截至 2025 年 12 月 12 日，2025 年 1-12 月北交所合计过会 43 家企业，合计上市 24 家 企业，其中 2025 年 11-12 月北交所合计过会 16 家企业。2025 年 7-12 月北交所 网上发行有效申购户数+冻结资金中枢整体稳定在均值59.95万户和7039.73亿元 左右。从 2025 年北交所新股申购中签率来看，2025 ...